Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.